Skip to main content
. 2006 Oct 9;26(24):9338–9351. doi: 10.1128/MCB.01032-06

FIG. 1.

FIG. 1.

Analysis of Irs-1 involvement in PyV-MT mammary tumor development. (A) Female PyV-MT and PyV-MT::Irs1−/− mice were monitored for the age at which mammary tumors were first palpable. The mean age in days for palpable tumors (± SEM) (P > 0.05) is shown. The number of mice analyzed for each genotype is indicated. (B) Female PyV-MT and PyV-MT::Irs1−/− mice were analyzed for their total tumor burden at 80 days of age. The mean tumor volume for each genotype (± SEM) (P > 0.05) is shown. The number of mice analyzed is indicated. (C) Biochemical analysis of representative PyV-MT and PyV-MT::Irs1−/− mammary tumors. Aliquots of mammary tumor extracts that contained equivalent amounts of total protein were immunoblotted with antibodies specific for Irs-1, Irs-2, insulin receptor (IR) β-subunit, IGF-1R β-subunit, cyclin D1, β4, or β-actin. WT, PyV-MT mice; Irs1−/−, PyV-MT::Irs1−/− mice. (D and E) Sections from PyV-MT (D) and PyV-MT::Irs1−/− (E) tumors were stained with antibodies specific for ERα. Inset, normal glands showing positive ERα staining.